Patents

Patent issued for large-scale AAV vector production methods

Published in Gene Therapy Weekly, August 29th, 2002

Avigen, Inc., (AVGN) announced it has been granted a patent covering manufacturing methods for large-scale production of AAV vectors, United States Patent No. 6,416,992, titled "Compositions and methods for producing recombinant adeno-associated virus."

This patent covers methods for producing AAV vectors in large amounts or high titers.

"Avigen continues to make progress in optimizing efficient, high-yield production and purification methods for AAV vector manufacturing to support the commercialization of AAV-based gene therapy products," said John Monahan, PhD, Avigen's president and CEO.

"This patent covers the utilization of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-08-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry